Since Avalanche (AVAX) moved from little-to-no volatility last month, the price remained in a consolidation phase with choppy price action. It attempted a breakout but failed due to rejections. The mid-March bounce saw AVAX through a decent recovery but failed to extend positive actions beyond the critical $18.3 resistance level as a result of a